Our team.
We are a dynamic team from diverse nationalities and backgrounds, united by our commitment to groundbreaking science and patient-oriented drug discovery. With expertise in chemistry, biology, and bioinformatics, we are passionate about unlocking the therapeutic potential of solute carrier (SLC) proteins and making a meaningful impact on human health.
Our story.
Solgate was founded in 2020 as a spin-off from CeMM/ÖAW and IST Austria. SLC proteins, a family of membrane transporters, are crucial to cellular function, metabolism, and health, yet their vast potential remains untapped. Over the years, our co-founders have been spearheading key research on proteins from this superfamily, both by elucidating functions of specific transporters as well as large efforts to generate reagents and datasets through the IMI-funded ReSOLUTE initiative. Leveraging our expertise in SLC biology, we are dedicated to pioneering drug discovery for this target class. Given their importance in human health and the limited exploration of SLCs in drug discovery, we are committed to closing this gap through technology development.
Our story.
Solgate was founded in 2020 as a spin-off from CeMM/ÖAW and IST Austria. SLC proteins, a family of membrane transporters, are crucial to cellular function, metabolism, and health, yet their vast potential remains untapped. Over the years, our co-founders have been spearheading key research on proteins from this superfamily, both by elucidating functions of specific transporters as well as large efforts to generate reagents and datasets through the IMI-funded ReSOLUTE initiative. Leveraging our expertise in SLC biology, we are dedicated to pioneering drug discovery for this target class. Given their importance in human health and the limited exploration of SLCs in drug discovery, we are committed to closing this gap through technology development.
Our mission.
We are building on the growing knowledge and interest in this target class to develop small-molecule drugs targeting SLC proteins. Through cutting-edge technology, we enhance the druggability of SLCs to make the development of new modalities possible. Our mission is to unlock the therapeutic potential of SLCs and develop novel treatments by targeting the transporters that control critical pathways in human disease. Ultimately, we aim to advance SLC-based drugs to improve the lives of patients and families affected by these conditions.
Our mission.
We are building on the growing knowledge and interest in this target class to develop small-molecule drugs targeting SLC proteins. Through cutting-edge technology, we enhance the druggability of SLCs to make the development of new modalities possible. Our mission is to unlock the therapeutic potential of SLCs and develop novel treatments by targeting the transporters that control critical pathways in human disease. Ultimately, we aim to advance SLC-based drugs to improve the lives of patients and families affected by these conditions.
Our approach.
We have developed an innovative platform that combines advanced chemical, biological, and computational technologies to accelerate the discovery of small molecules targeting SLCs with key functions in disease. With the support of private investors as well as public funding by the Austrian Research Promotion Agency (FFG) and the Austria Wirtschaftsservice (aws), we are well-positioned to advance our pipeline of SLC-targeting compounds and progress them towards clinical development.
